Hiroyuki Suzuki, Kento Kannaka, Mizuki Hirayama, Tomoki Yamashita, Yuta Kaizuka, Ryota Kobayashi, Takahiro Yasuda, Kazuhiro Takahashi, Tomoya Uehara. In vivo stable 211At-labeled prostate-specific membrane antigen-targeted tracer using a neopentyl glycol structure. EJNMMI Radiopharmacy and Chemistry. 2024
Masatoshi Tada, Yuta Kaizuka, Kento Kannaka, Hiroyuki Suzuki, Taiki Joho, Kazuhiro Takahashi, Tomoya Uehara, Hiroshi Tanaka. Development of a neopentyl 211At-labeled activated ester providing in vivo stable 211At-labeled antibodies for targeted alpha therapy. ChemMedChem. 2024
Hiroyuki Suzuki, Masato Matsukawa, Rikako Madokoro, Yui Terasaka, Kento Kannaka, Tomoya Uehara. Reduction of the hepatic radioactivity levels of [111In]In-DOTA-labeled antibodies via cleavage of a linkage metabolized in lysosomes. Nuclear Medicine and Biology. 2024. 132-133. 108910
Hiroyuki Suzuki, kento kannaka, Tomoya Uehara. Approaches to Reducing Normal Tissue Radiation from Radiolabeled Antibodies. Pharmaceuticals. 2024
Yuta Kaizuka, Hiroyuki Suzuki, Tadashi Watabe, Kazuhiro Ooe, Atsushi Toyoshima, Kazuhiro Takahashi, Koichi Sawada, Takashi Iimori, Yoshitada Masuda, Takashi Uno, et al. Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics. EJNMMI Radiopharmacy and Chemistry. 2024. 9. 1
A novel approach to produce astatine-211-labeled agents for effective and safe targeted alpha therapy.
(The 4th CRI-CGI-Chiba symposium in Chemistry and Biomedical Sciences 2024)
Reduction of renal radioactivity levels of 111In-labeled antibody fragments.
(The 3rd CRI-CGI-Chiba Symposium in Chemistry 2023)